ANIP — ANI Pharmaceuticals, Inc.

Summary of ANI Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Net Revenues: $237.5 million, up 20% year-over-year.
• Cortrophin Gel Revenues: $75.1 million, a 42% increase year-over-year.
• ILUVIEN Revenues: $19.3 million, up 20% year-over-year.
• Generics Revenues: $105.4 million, a 7% increase year-over-year.
• Adjusted EBITDA: $63 million, up 24% year-over-year.
• Adjusted Non-GAAP EPS: $2.05, compared to $1.70 in the prior year.
• Cash Position: $311.2 million in unrestricted cash, with cash flow from operations at $58.4 million.
• Debt: $625 million in outstanding debt, with a gross leverage ratio of 2.6x.

2. Strategic Updates and Business Highlights

• ANI is focused on transforming into a leading Rare Disease company, with Cortrophin Gel as a key asset.
• Significant growth in Cortrophin Gel driven by new patient starts and expansion into acute gouty arthritis flares.
• The company has expanded its Rare Disease organization and expects full deployment of a new commercial team by the end of June.
• A licensing agreement with Harmony Biosciences was established, generating an upfront fee of $15 million and potential future royalties.
• The Generics business continues to perform well, with plans for 10-15 product launches annually.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $1.08 billion to $1.14 billion.
• Cortrophin Gel Revenue Guidance: Reaffirmed at $540 million to $575 million.
• Adjusted EBITDA Guidance: Increased to $285 million to $300 million.
• ILUVIEN Revenue Guidance: Reaffirmed at $78 million to $83 million.
• The company anticipates strong sequential growth in the second half of 2026, particularly from Cortrophin Gel.

4. Challenges and Points of Concern

• Insurance Reverifications: Delays in the first quarter impacted sales, particularly in January and February, although momentum has since improved.
• Market Competition: The ACTH category is becoming more competitive, which may affect pricing and access dynamics.
• Payer Access: Ongoing challenges with payer access and reimbursement processes, particularly for ILUVIEN.
• Seasonality: The first quarter's performance was affected by typical seasonality, which could recur in future quarters.

5. Notable Q&A Insights

• Cortrophin Growth: Majority of growth is expected from core indications (rheumatology, nephrology, etc.), with gout expansion anticipated to have a more significant impact in 2027.
• Payer Management: The company is focused on expanding access to ACTH therapy and has seen a shift in prescriber demographics.
• Harmony Licensing: The $10 million in development milestones from the Harmony agreement is included in the updated guidance, but the specifics of the development timeline remain confidential.
• Patient Support: Increased patient support efforts were noted, particularly in response to higher patient volumes and insurance reverification issues.

Overall, ANI Pharmaceuticals reported strong Q1 results, raised its guidance for 2026, and is making strategic investments in its Rare Disease business, though it faces challenges related to payer access and market competition.